Skip to main content

EULAR 2025 Congress

EULAR 2025 Congress

11–14 June | Barcelona

The annual congress of the European Alliance of Associations for Rheumatology brought together leading experts to explore the latest advances in inflammatory arthritis, osteoarthritis, lupus, vasculitis, and more. We bring you updates and breaking news.

Another promising signal for GLP-1 drugs, this time in fibromyalgia

In a large database analysis, use of GLP-1 receptor agonists was associated with a reduced symptom burden in people with fibromyalgia, but further studies with validated outcome measures are needed.

Read more

Rheumatology Update

Covering the latest advances and keeping your practice up to date. Receive newsletters personally curated for the busy rheumatologist.

No increase in cancer risk with JAK inhibitors in RA

Use of JAK inhibitors to treat rheumatoid arthritis is not associated with an increased risk for cancer compared with TNF inhibitors.

Reassuring findings for zoster vaccine use in inflammatory RMDs

The recombinant zoster vaccine is well tolerated by patients with inflammatory rheumatic and musculoskeletal diseases, with only a few incidences of flare and serious adverse events.

Reduction in MACE risk an additional benefit of treat to target in gout

  • 19-06-2025
  • Gout
  • News

Meeting serum urate targets within a year of initiating urate-lowering treatment may significantly lower the risk for major adverse cardiovascular events in people with gout.

Better axSpA outcomes after intervention with Axia app

A new app-based digital therapy leads to significant improvements in disease activity, functional status, and quality of life in patients with stable, treated axial spondyloarthritis.

POETYK trial shows clinical benefit of deucravacitinib in PsA

Treatment with the TYK2 inhibitor deucravacitinib improved disease activity, joint and skin symptoms, and quality of life among people with active psoriatic arthritis participating in the POETYK PsA-1 trial.

Read more

T2T strategy with secukinumab effective in PsA in STAMP study

Early treatment with secukinumab according to a treat-to-target strategy in patients with psoriatic arthritis led to a significant clinical response within 3 months.

Vectorcardiography identifies SSc patients at high risk for PH

Ventricular gradient optimized for right ventricular pressure overload is higher in systemic sclerosis patients with pulmonary hypertension.

Great inequality in access to rheumatology care within Europe

  • 30-06-2025
  • Care
  • News

The Rheumafacts study has found that in about half of European countries, patients do not have full access to modern medication and reimbursement for non-pharmacological treatments.

Patient-perceived residual symptoms predict axSpA flare-ups

The presence of patient-reported residual symptoms during inactive disease or low disease activity is associated with an increased flare risk in people with axial spondyloarthritis.

Higher JIA risk after fertility treatment, especially in boys

Children of mothers who have undergone fertility treatment may have a higher risk for developing juvenile idiopathic arthritis.

Persistence and efficacy of ixekizumab versus other DMARDs in PsA

Patients with psoriatic arthritis treated with ixekizumab have a higher chance of remission than those given interleukin-12/23 and interleukin-23 inhibitors.

Can social robots replace the rheumatologist?

Both patients with rheumatic diseases and healthcare professionals find social robots potentially valuable in outpatient settings, especially for information delivery and patient education support.

Work-focused intervention for RA or axSpA found to be (cost-)effective

A physiotherapist-led, work-focused intervention did not lead to better work-related outcomes in people with rheumatoid arthritis or axial spondyloarthritis, but it may prove to be cost-effective.

Stay up to date with more from Springer Medicine

Keynote webinar | Spotlight on advances in lupus

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Learn more about novel biomarkers for diagnosis and monitoring, and familiarize yourself with current and emerging targeted therapies.

Elevate your expertise in aplastic anemia (Link opens in a new window)

  • Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Developed by: Springer Health+ IME
Supported by:
  • Pfizer
Podcast

Episode 17: Challenges of developing DMOADs

  • Podcast

Despite multiple attempts, no DMOAD is yet approved for clinical use. Prof. Ali Mobasheri takes us through the main challenges, the work being done to make these so-called utopia drugs a reality, and discusses other advances that offer hope in the meantime.

Prof. Ali Mobasheri